Skip to main content
Erschienen in: Drugs & Aging 1/2010

01.01.2010 | Original Research Article

Differential Impact of NSAIDs on Rate of Adverse Events that Require Hospitalization in High-Risk and General Veteran Populations

A Retrospective Cohort Study

Erschienen in: Drugs & Aging | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Many observational studies in the general population have demonstrated an increased risk of adverse events associated with NSAIDs, including gastrointestinal bleeds, congestive heart failure, acute renal failure, hypertension and acute myocardial infarction. Few studies, however, have explored outcomes in populations considered to be more vulnerable to their effects.

Objective

To determine the rate of adverse events requiring hospitalization that are associated with NSAIDs in two high-risk veteran populations and the general veteran population.

Methods

In this retrospective cohort study, we identified veterans being dispensed medicines for diabetes mellitus (diabetes cohort), those receiving renin-angiotensin system medicines and frusemide (furosemide) concurrently (ACE inhibitors/angiotensin II type 1 receptor antagonists [angiotensin receptor blockers; ARBs] and frusemide cohort), or at least one other medicine (general population/reference cohort). The primary endpoint was hospitalization with a primary diagnosis of congestive heart failure, gastrointestinal ulcer, acute renal failure, acute myocardial infarction or hypertension. Hospitalization rates during the period of non-exposure and the 30-day period after a subject was first dispensed an NSAID were compared using Poisson regression.

Results

There was a significant increase in risk of all hospitalizations of interest in the exposed period compared with the unexposed period in the diabetes cohort (incidence rate ratio [IRR] 1.31; 95% CI 1.08, 1.60), ACE inhibitor/ARB and frusemide cohort (IRR 1.34; 95% CI 1.13, 1.58) and reference cohort (IRR 1.47; 95% CI 1.30, 1.66). The incidence rates demonstrate that for every 10 000 veterans treated for 30 days with NSAIDs, there were 20 extra hospitalizations in the diabetes population, 30 additional hospitalizations in the ACE inhibitor/ARB and frusemide cohort and 6 extra hospitalizations in the reference population compared with those not treated with NSAIDs.

Conclusions

NSAID use is associated with an increased risk of hospitalization in all groups, with similar risk ratio estimates. However, the clinical implications were greater in the high-risk populations, in which more hospitalizations were observed. Consideration may need to be given to differential presentation of risk information to clinicians.
Literatur
1.
Zurück zum Zitat Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331(7528): 1310–6PubMedCrossRef Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331(7528): 1310–6PubMedCrossRef
2.
Zurück zum Zitat Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731–8PubMedCrossRef Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731–8PubMedCrossRef
3.
Zurück zum Zitat Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27(6): 411–20PubMedCrossRef Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27(6): 411–20PubMedCrossRef
4.
Zurück zum Zitat Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325(7365): 624–9PubMedCrossRef Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325(7365): 624–9PubMedCrossRef
5.
Zurück zum Zitat Norgard B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004; 19(7): 817–25PubMedCrossRef Norgard B, Pedersen L, Johnsen SP, et al. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004; 19(7): 817–25PubMedCrossRef
6.
Zurück zum Zitat Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14(2): 240–6PubMed Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003; 14(2): 240–6PubMed
7.
Zurück zum Zitat Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005; 330(7504): 1370–5PubMedCrossRef Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005; 330(7504): 1370–5PubMedCrossRef
8.
Zurück zum Zitat Huerta C, Varas-Lorenzo C, Castellsague J, et al. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006; 92(11): 1610–5PubMedCrossRef Huerta C, Varas-Lorenzo C, Castellsague J, et al. Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006; 92(11): 1610–5PubMedCrossRef
9.
Zurück zum Zitat Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363(9423): 1751–6PubMedCrossRef Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363(9423): 1751–6PubMedCrossRef
10.
Zurück zum Zitat Huerta C, Castellsague J, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9PubMedCrossRef Huerta C, Castellsague J, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9PubMedCrossRef
11.
Zurück zum Zitat Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006; 164(9): 881–9PubMedCrossRef Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol 2006; 164(9): 881–9PubMedCrossRef
12.
Zurück zum Zitat Nietert PJ, Ornstein SM, Dickerson LM, et al. Comparison of changes in blood pressure measurements and anti-hypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 2003; 23(11): 1416–23PubMedCrossRef Nietert PJ, Ornstein SM, Dickerson LM, et al. Comparison of changes in blood pressure measurements and anti-hypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy 2003; 23(11): 1416–23PubMedCrossRef
13.
Zurück zum Zitat Solomon DH, Schneeweiss S, Levin R, et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44(2): 140–5PubMedCrossRef Solomon DH, Schneeweiss S, Levin R, et al. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44(2): 140–5PubMedCrossRef
14.
Zurück zum Zitat Yood MU, Watkins E, Wells K, et al. The impact of NSAID or COX-2 inhibitor use on the initiation of anti-hypertensive therapy. Pharmacoepidemiol Drug Saf 2006; 15(12): 852–60PubMedCrossRef Yood MU, Watkins E, Wells K, et al. The impact of NSAID or COX-2 inhibitor use on the initiation of anti-hypertensive therapy. Pharmacoepidemiol Drug Saf 2006; 15(12): 852–60PubMedCrossRef
15.
Zurück zum Zitat Zhao SZ, Burke TA, Whelton A, et al. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 2002; 8(15 Suppl.): S401–13PubMed Zhao SZ, Burke TA, Whelton A, et al. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 2002; 8(15 Suppl.): S401–13PubMed
16.
Zurück zum Zitat Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27(14): 1657–63PubMedCrossRef Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27(14): 1657–63PubMedCrossRef
17.
Zurück zum Zitat Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98(3): 266–74PubMedCrossRef Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98(3): 266–74PubMedCrossRef
18.
Zurück zum Zitat Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330(7504): 1366–72PubMedCrossRef Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330(7504): 1366–72PubMedCrossRef
19.
Zurück zum Zitat Jick H, Kaye JA, Russmann S, et al. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006; 26(10): 1379–87PubMedCrossRef Jick H, Kaye JA, Russmann S, et al. Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy 2006; 26(10): 1379–87PubMedCrossRef
20.
Zurück zum Zitat Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165(9): 978–84PubMedCrossRef Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165(9): 978–84PubMedCrossRef
21.
Zurück zum Zitat Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068–73PubMedCrossRef Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068–73PubMedCrossRef
22.
Zurück zum Zitat Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169(2): 141–9PubMedCrossRef Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169(2): 141–9PubMedCrossRef
23.
Zurück zum Zitat Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113(25): 2906–13PubMedCrossRef Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113(25): 2906–13PubMedCrossRef
24.
Zurück zum Zitat Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the ‘triple whammy’. Br J Clin Pharmacol 2005; 59(2): 239–43PubMedCrossRef Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the ‘triple whammy’. Br J Clin Pharmacol 2005; 59(2): 239–43PubMedCrossRef
25.
Zurück zum Zitat Roughead EE, Ramsay E, Pratt N, et al. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug Saf 2008; 31(11): 997–1003PubMedCrossRef Roughead EE, Ramsay E, Pratt N, et al. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug Saf 2008; 31(11): 997–1003PubMedCrossRef
26.
Zurück zum Zitat Cox-2 selective NSAIDs: new wonder drugs? Sydney (NSW): National Prescribing Service Ltd, 2001 Cox-2 selective NSAIDs: new wonder drugs? Sydney (NSW): National Prescribing Service Ltd, 2001
27.
Zurück zum Zitat Vitry A, Wong S, Roughead EE, et al. Validity of medication-based comorbidity indices in the Australian elderly population. Aust N Z J Public Health 2009; 33: 126–30PubMedCrossRef Vitry A, Wong S, Roughead EE, et al. Validity of medication-based comorbidity indices in the Australian elderly population. Aust N Z J Public Health 2009; 33: 126–30PubMedCrossRef
28.
Zurück zum Zitat Australian Bureau of Statistics (ABS). Information paper: census of population and housing. Socio-economic indexes for areas, Australia, 2001. Canberra (ACT): ABS, 2003 Australian Bureau of Statistics (ABS). Information paper: census of population and housing. Socio-economic indexes for areas, Australia, 2001. Canberra (ACT): ABS, 2003
29.
Zurück zum Zitat Solomon DH, Schneeweiss S, Glynn R, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115:715–20PubMedCrossRef Solomon DH, Schneeweiss S, Glynn R, et al. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003; 115:715–20PubMedCrossRef
Metadaten
Titel
Differential Impact of NSAIDs on Rate of Adverse Events that Require Hospitalization in High-Risk and General Veteran Populations
A Retrospective Cohort Study
Publikationsdatum
01.01.2010
Erschienen in
Drugs & Aging / Ausgabe 1/2010
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11531250-000000000-00000

Weitere Artikel der Ausgabe 1/2010

Drugs & Aging 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.